Mineralys Therapeutics, Inc. MLYS
$24.11
▼ -1.34% 24H
About
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldos…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees76
TickerMLYS
Statistics
Market Cap$1.99B
Revenue (TTM)—
Net Income-$154.7M
Net Margin—
EPS$-2.29
P/E-10.31
P/S—
P/B3.00
EV/EBITDA-7.67
ROE-31.0%
Dividend Yield—
Price$24.11
Data: Twelve Data · Revenue = mcap / P/S